Tissue Transglutaminase (TG2) is a potential therapeutic target in the treatment of chemoresistant breast cancer

0044 English OPEN
Rajasekaran, Vidya;

Tissue transglutaminase (TG2) has been suggested to be a key player in the progression and metastasis of chemoresistant breast cancer. One of the foremost survival signalling pathways implicated in causing drug resistance in breast cancer is the constitutive activation ... View more
  • References (15)
    15 references, page 1 of 2

    Hitomi, K., Kanehiro, S., Ikura, K., Maki, M., (1999). Characterization of recombinant mouse epidermal-type transglutaminase (TGase 3): regulation of its activity by proteolysis and guanine nucleotides.. J Biochem, 125, pp. 1048.

    Hitomi, K., Presland, RB., Nakayama, T., Fleckman, P., Dale, BA., Maki, M., (2003).

    Analysis of epidermal-type transglutaminase (transglutaminase 3) in human stratified epithelia and cultured keratinocytes using monoclonal antibodies. J Dermatol Sci, 32, pp. 95.

    Ho, G., Gregory, EJ., Smirnova, IV., Zoubine, MN., Festoff, BW., (1994). Crosslinking of beta-amyloid protein precursor catalyzed by tissue transglutaminase. FEBS Lett, 349, pp. 151.

    Hoffmann, A., Natoli, G., Ghosh, G., (2006). Transcriptional regulation via the nfkb signalling molecule. oncogene, 25, pp. 6706.

    Huber, M., Azoitei, N., Baumann, B., Grünert, S., Sommer, A., Pehamberger, H., Kraut, N., Beug, H., Wirth, T., (2004). NF-κB is essential for epithelialmesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest, 114, pp. 569.

    Hui, L, Zheng, Y., Yan, Y., Bargonetti, J., Foster, D.A. (2006). Mutant p53 in MDAMB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phsopholipase D. Oncogene 25, pp 7305 Hunter, I., Sigmundsson, K., Beauchemin, N., Obrink, B., (1998). The cell adhesion molecule C-CAM is a substrate for tissue transglutaminase. FEBS Letters, 425, pp. 141.

    Hupp, T.R., Lane, D.P., Ball, K.L (2000). Strategies for manipulating the p53 pathway in treatment of human cancer. Biochemistry Journal 352, pp 1.

    Hwang, J., Mangala, LS., Fok, JY., Lin, YG., Merritt, WM., Spannuth, WA., Nick, AM., Fiterman, DJ., Vivas-Mejia, PE., Deavers, MT., Coleman, RL., Lopez-Berestein, G., Mehta, K., Sood, AK., (2008). Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res, 68, pp. 5849.

    Iacobuzio-Donahue, CA., Maitra, A., Olsen, M., Lowe, AW., van Heek, NT., Rosty, C., Walter, K., Sato, N., Parker, A., Ashfaq, R., Jaffee, E., Ryu, B., Jones, J., Eshleman, JR., Yeo, CJ., Cameron, JL., Kern, SE., Hruban, RH., Brown, PO., Goggins, M., (2003). Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol, 162, pp. 1151.

  • Related Research Results (1)
  • Metrics
Share - Bookmark